BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration (FDA) has officially closed its inspection of a single site involved in the TRANQUILITY II Phase 3 trial under 21 C.F.R.20.64(d)(3). The FDA’s designation of “Voluntary Action Indicated” (VAI) signals that while minor issues may have been identified, no regulatory action is required, further […]
Telomir Pharmaceuticals (NASDAQ: TELO) has achieved a major scientific breakthrough by stabilizing Silver(II) (Ag²⁺) using its proprietary compound, Telomir-1. This advancement overcomes a key challenge in silver-based medicine, unlocking new possibilities for antimicrobial treatments, wound care, and infection-resistant medical coatings. Silver(II) offers superior antibacterial action, faster wound healing, and immune-modulating properties compared to traditional Silver(I) […]
flyExclusive (NYSE American: FLYX), a leading provider of premium jet charter experiences, has entered into a definitive agreement to acquire the aviation business of Jet.AI (NASDAQ: JTAI). The deal will allow flyExclusive to expand its fleet and market presence while enabling Jet.AI to transition into a pure-play AI solutions company. Under the terms of the […]
Inspira Technologies (NASDAQ: IINN) has reported promising pre-clinical results for its bio-electronic anti-bacterial IV dressing technology, developed in collaboration with Ennocure MedTech Ltd. The innovative solution aims to combat bloodstream infections, a critical issue affecting an estimated 250,000 patients worldwide each year due to contaminated intravenous (IV) lines. In ex-vivo testing using a porcine skin […]
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug eRapa, a proprietary encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis (FAP). This designation is designed to accelerate the development and review process for drugs that address serious conditions with […]
Conduit Pharmaceuticals (NASDAQ: CDT) announced the successful completion of Phase I in its AI-driven drug development collaboration with Sarborg Limited. With all milestones achieved, the partnership is now transitioning to Phase II, which will focus on developing personalized software dashboards to improve operational efficiency and decision-making. Phase I, initiated in December 2024, laid the groundwork […]
Quantum BioPharma (QNTM), a biopharmaceutical company focused on innovative biotech solutions, announced that its licensee, Celly Nutrition Corporation, has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering (IPO) on a major U.S. exchange. Celly Nutrition, the company behind unbuzzd™—a scientifically proven beverage that accelerates […]
Inspira Technologies (Nasdaq: IINN), a leader in life-support innovation, has announced the integration of a next-generation oxygenation indicator into its AI-powered HYLA™ blood sensor. This enhancement is designed to enable rapid, continuous detection of oxygen-related conditions without requiring intermittent blood draws, marking a significant advancement in critical care monitoring. The newly integrated oxygenation indicator facilitates […]
Quantum BioPharma (NASDAQ: QNTM) announced compelling results from a clinical trial evaluating its dietary supplement, unbuzzd. The double-blind, randomized, placebo-controlled study demonstrated that unbuzzd significantly accelerates alcohol metabolism, lowers blood alcohol concentration (BAC), and reduces symptoms of intoxication and hangovers. Participants in the trial, aged 21 to 43, experienced a rapid reduction in BAC—more than […]
GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, announced promising results from its Phase 2b clinical trial of GH001, an inhalable mebufotenin product candidate, for patients with treatment-resistant depression (TRD). The randomized, double-blind, placebo-controlled study demonstrated that GH001 achieved its primary endpoint, delivering an ultra-rapid antidepressant effect. Patients treated with GH001 experienced a significant […]
